Burosumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Burosumab |
| DrugBank ID | DB14012 |
| Brand Names (EU) | Crysvita |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 96.93% |
Approved Indication (EMA)
Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | renal osteodystrophy | 96.93% | DL |
| 2 | impaired renal function disease | 95.92% | DL |
| 3 | non-renal secondary hyperparathyroidism | 95.78% | DL |
| 4 | bone remodeling disease | 95.49% | DL |
| 5 | hyperparathyroidism, transient neonatal | 95.05% | DL |
| 6 | severe nonproliferative diabetic retinopathy | 94.58% | DL |
| 7 | diabetic retinopathy | 93.96% | DL |
| 8 | diabetic cataract | 90.64% | DL |
| 9 | hypocalcemic rickets | 89.65% | DL |
| 10 | cortical cataract | 87.73% | DL |
| 11 | nuclear senile cataract | 87.73% | DL |
| 12 | immature cataract | 87.52% | DL |
| 13 | craniostenosis cataract | 87.52% | DL |
| 14 | diabetes mellitus type 2 associated cataract | 87.52% | DL |
| 15 | mature cataract | 87.52% | DL |
| 16 | tetanic cataract | 87.52% | DL |
| 17 | senile cataract | 87.47% | DL |
| 18 | familial primary hyperparathyroidism | 87.33% | DL |
| 19 | epiglottitis | 86.35% | DL |
| 20 | gastric linitis plastica | 85.46% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.